News

An advanced PARP inhibitor, Lynparza is the first targeted treatment which is being developed by the companies to exploit DNA damage response (DDR) pathway deficiencies to kill cancer

Erasca’s ERAS-007 is currently being evaluated alone or in combination with different inhibitors to upstream MAPK pathway nodes as part of the MAPKlamp strategy. Under the collaboration, Lilly

An autologous TCR-T cell treatment, NTLA-5001 is intended to target the Wilms’ Tumor (WT1) antigen, which is highly expressed in AML and several other hematologic and solid tumours.

The company sought approval for the combination therapy to treat previously untreated mantle cell lymphoma (MCL) adult patients not suitable for autologous stem cell transplantation (ASCT). Jointly developed

The company intends to utilise the funds to continue its ongoing Phase Ib clinical trial and begin two additional Phase Ib studies this year. It also plans to

A drug-free nasal spray, Bentrio is designed for personal protection against airborne viruses and allergens. It forms a protective gel layer on the nasal mucosa upon application into

As per the terms of the updated and restated deal, Helsinn will obtain an exclusive license for infigratinib commercialisation in the US. The company will also develop, produce,

The funding round included new investors Schroders Capital, 3B Future Health Fund, Caribou Property, and British Patient Capital. Existing investors Epidarex Capital and ALSA Ventures have also participated

Co-led by Canaan Partners and Red Tree Venture Capital, the financing round included significant investment from Johnson & Johnson Innovation – JJDC. SV Health Investors and Novo Holdings